????Exciting News from Deverra Therapeutics!???? We are thrilled to announce that Debora Barton, MD?has joined our Advisory Board. Dr. Barton is a highly experienced oncologist with over 24 years of expertise in clinical practice, research, and the biotechnology/pharmaceutical industry. She has a distinguished background in oncology, spanning both academic medicine—where she served as a practicing physician and clinical investigator—and industry, where she contributed to the development of innovative cancer therapies. Dr. Barton spent a decade at Novartis and Celgene, advancing through roles in Medical Affairs and Clinical Development. She then transitioned into senior executive and C-suite leadership positions, as well as board roles, at several cutting-edge biotechnology companies focused on adoptive cellular therapies and radiopharmaceuticals. Her leadership experience includes positions at Advanced Accelerator Applications (a Novartis Company), Iovance Biotherapeutics (Tumor Infiltrating Lymphocytes), Carisma Therapeutics (CAR-Macrophages and CAR-Monocytes), TScan Therapeutics (TCR-T cell therapies), Arovella Therapeutics (CAR-iNKT), and NKILT Therapeutics (CIR-NK). Dr. Barton earned her MD from Pontificia Universidade Católica de S?o Paulo (PUC-SP) and completed her oncology fellowship at the Federal University of S?o Paulo (UNIFESP), Brazil. Dr. Barton brings extensive clinical expertise that will be instrumental in advancing Deverra’s allogeneic myeloid program to the clinic. Her insights and experience in clinical development align perfectly with our mission to revolutionize cell therapy for patients. We look forward to her valuable contributions as we continue to drive innovation in the field. Welcome to the team, Dr. Barton! #CellTherapy #ClinicalDevelopment #Biotechnology #Innovation #Allogeneic About Deverra Therapeutics: Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
关于我们
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- 网站
-
https://www.deverratx.com
Deverra Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Seattle
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
获取路线
US，Seattle
Deverra Therapeutics员工
动态
-
?? Exciting News! ?? Deverra is thrilled to share that preliminary clinical outcomes using dilanubicel in an investigator initiated trial (IIT) led by Dr. Filippo Milano at the Fred Hutch will be featured as an oral presentation at the upcoming ASH Annual Meeting 2024! ?? Presentation Title: Dilanubicel, a Non-HLA-Matched Pooled Universal Product, Transforming Single Cord Blood Transplantation Success Rates ?? Date & Time: Saturday, December 7 at 5:00pm ?? Location: Session 721, San Diego Convention Center, Room 6DE Post-transplant leukemic relapse is a leading cause of treatment failure in stem cell transplant. ?This presentation will highlight the safety of infusing our product dilanubicel, a non-HLA matched and off-the-shelf cellular immunotherapy derived from pooled donors, to enhance graft-versus- leukemia in the setting of myeloablative cord blood transplant. The proposed mechanism of action here is similar to the anti-leukemic effects demonstrated when dilanubicel was used in the setting of upfront AML therapy, activating a host-mediated anti-leukemic response with improved remission rates. We are grateful to our partners at Fred Hutch for their incredible dedication and collaboration. Achieving and maintaining remission is critical for the survival of patients with leukemia; dilanubicel represents a potential cost effective and clinically accessible therapy to realizing this goal. https://lnkd.in/g5P8TaRb #ASH2024 #celltherapy #dilanubicel #leukemia #AML #allogeneic
-
Happy World Cord Blood Day!!!
Founder and Chief Scientific Officer, EVP of Research and Development at Deverra Therapeutics; Clinical Professor and Attending Physician, Stem Cell Transplant, Seattle Children's Hospital/University of WA
???? Celebrating World Cord Blood Day! ???? Today is #WorldCordBloodDay and a time to reflect on the amazing career that I have had that has centered around the use of this often-overlooked resource and its potential to save lives. Not only can cord blood be used as a donor for those in need of a stem cell transplant with ~40,000 cord blood transplants performed to date worldwide, this beautiful bag of blood collected without risk at the time of birth can also be used as a source of starting cells to generate life-saving cellular therapies, as we are doing at #Deverra. This is only the beginning. The future is bright, and I am confident that we will continue to see tremendous progress using cord blood to save lives. Today especially – I am so very grateful for the team I work with, the many colleagues, physicians and researchers who work tirelessly to advance science and bring hope to patients, the mothers who have donated their “medical waste”, and the cord blood banks who store this “bag” of powerful potential. Finally – to all the patients I have been so furtunate to know and to help care for, I see you and think of you all often. Just this past week, the public cord blood banks were awarded the “Be There Award” by the NMDP at the ONE Forum. It couldn’t be more timely. Please watch the video below to learn more about what the public banks do. https://lnkd.in/gEndYXhk Happy World Cord Blood Day! #cordblood #donorforall #nmdp #savethecordbloodsavetheworld #grateful
Be There Award | The ONE Forum 2024
https://www.youtube.com/
-
Jared Schuster, Colleen Delaney, and Joanne Kurtzburg discussing the benefits and opportunities of cord blood over other starting materials, consideration for licensed vs unlicensed unit selection (and cord blood bank qualification), consent considerations, and relevant biological differences between cord vs peripheral immune cells. #advancedtherapies #celltherapy #cordblood #CBU
-
-
Going to the 2024 AABB Annual Meeting in Houston this week? If so, go see Colleen Delaney, our scientific founder and CSO, who will participate on an important panel discussing starting material for allogeneic cellular therapies. She is also giving a talk on Deverra's unique stem cell expansion and cell differentiation platform using pooled donor cord blood derived CD34+ cells to derive multiple immunocellular therapy products. We hope to connect with many of you there! #AABB24 #CordBlood #allogeneic #biotherapies
Founder and Chief Scientific Officer, EVP of Research and Development at Deverra Therapeutics; Clinical Professor and Attending Physician, Stem Cell Transplant, Seattle Children's Hospital/University of WA
I’m excited to share that I’ll be speaking at the 2024 AABB Annual Meeting, taking place Oct. 19-22 in Houston. Join me and fantastic colleagues, Priya Baraniak, Heather Munoz, Robert Tressler, Diana HERNANDEZ, Monday morning at 9:30am for an important panel discussion on the importance of cellular starting material in the development of allogeneic cell therapies, moderated by Jeff Wren and Linda S Barnes. Then, in the afternoon, come to the session on Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation, to hear from Larry Luchsinger, Adam Wilkinson and me and learn more about the translational research that is happening in the field of hematopoietic stem cells for therapeutic approaches. Looking forward to seeing everyone there! #AABB24 #allogeneiccelltherapies #biotherapies #cordblood #HSC
-
-
Colleen Delaney, Founder and CSO, presented Deverra's assets and product pipeline this morning at the Cell & Gene Meeting on the Mesa in Phoenix, AZ. So excited to participate in this conference, and we're looking forward to meeting this week with other pioneers in the GCT space! #CGMesa24 #cellandgenetherapy #allogeneiccelltherapy #oncology #dilanubicel #AML #monocytes #NKcells
-
-
?? Deverra Therapeutics is proud to be one of the companies selected for a company presentation at the upcoming Cell and Gene Meeting on the Mesa! Will you be there too? If so, come to our company presentation on Monday at 9:45am, Ballroom F and send us a note in the partnering system to meet. Our CSO and Founder Colleen Delaney and our VP of Discovery and Translational Research Erika von Euw, will be there and welcome the opportunity to meet with other industry pioneers and stakeholders in the CGT space. See you there!!! #CGMesa24 #cellandgenetherapy #allogeneiccelltherapy #AML #dilanubicel
-
-
We are thrilled to have presented at the Annual Cord Blood Connect meeting in Miami at the beginning of the month. Sponsored by the #CBA, this meeting is the only gathering dedicated to advancing the use of cord blood and birthing tissue to benefit patients and advance medicine! ?? It was an amazing experience to connect with some of the brightest minds in the field, exchange ideas, and explore new avenues for collaboration. We were inspired by the shared passion for innovation and the potential of cord blood to revolutionize healthcare. From groundbreaking discussions to exciting new friendships forged, this event was truly fantastic. A big thank you to everyone who made this year's Cord Blood Connect Meeting so special! See you again next year! Looking forward to the many partnerships and projects ahead! ?? #CBC2024 #CBC2025 #CordBloodSavesLives #CordBlood #CGT #Innovation
-
-
Stem Cell Manufacturing Market?Worth $21.8 billion by 2028 ??????? ???????????????? ?????? ????????????-https://lnkd.in/e2vDGMXa The global stem cell manufacturing market in terms of revenue was estimated to be worth $12.7 billion in 2023 and is poised to reach $21.8 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028 ?????? ?????????????????? ???????????????? ???? ???????? ???????????? ?????????????? Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Becton, Dickinson, and Company (US), Eppendorf AG (Germany), Corning Inc. (US), Bio-Rad Laboratories (US),?Takara Bio Group (Japan), Fujifilm Holdings Corporation (Japan), Getinge AB (Sweden), Terumo Corporation (Japan), etc ?????????? ?????????????????? ?????????????????? ???? ???????? ???????????? ???????????????? PT Prodia StemCell Indonesia Deverra Therapeutics????? INNOVIA BIOBANK ? Biogenuix Medsystems Pvt Ltd????? HebeCell Corp PL BioScience GmbH Anja Health? Society for Brain Mapping & Therapeutics (SBMT)????? Generate Life Sciences????? Cynata Therapeutics Future Health Biobank??? NextCell Pharma AB National Center for Cell Science Colorado Springs Orthopaedic Group????? Medistra Hospital?? Akari Therapeutics, Plc SSCB | Swiss Stem Cells Biotech | Bio-Banca Cellule Staminali????? Qkine Bioceltix? Epistem Ltd. DKMS BMST Foundation India????? Axent Biosciences??? AIVITA Biomedical, Inc.? CellVoyant WiCell Bacterin International, Inc.????? Nordic Biosite Biopelle MedCells Intl. FZ LLC??? Lifeline Cell Technology Stempeutics Research Private Limited????? Venkata Narayana Active Ingredients Pvt. Ltd.????? Morphocell Technologies??? XNK Therapeutics? Biological Industries Sartorius? Cordlife Group Limited?? ORF Genetics
-